Impel NeuroPharma Announces Publication of Pivotal Phase 3, Open-Label Stop 301 Study of INP104 (TRUDHESA™) for Treatment of Acute Migraine in the Journal Headache

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition

Matt Turner
Patient Affordability

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Suma Ramadas, PhD
Medical Affairs

Daniel Sontupe
Market Access